Vaccine, Immunity, and Cancer Directorate

Program Overview

The program helps inform public health decisions by providing data and analysis of antibody responses in a variety of clinical trials. Our translational science is focused on critical health concerns including cancer, HPV, and COVID-19.  

Our teams evaluate and validate serology assays and provide scientific and laboratory support for the development of new cancer preventive vaccines.

Program Innovations

In February 2022, the UK’s Joint Committee on Vaccination and Immunisation issued interim advice on a move to a one-dose schedule for the HPV vaccine for its routine adolescent programme. The HPV Serology Laboratory, through its work on the NCI Costa Rica Vaccine Trial, has provided considerable evidence demonstrating the long-term HPV immunogenicity following a single-dose vaccine to support this important move.

In response to the SARS-CoV-2 pandemic, the COVID-19 Serology Laboratory produced the U.S. Human SARS-CoV-2 Serology Standard in a collaboration with the National Cancer Institute and various other U.S. government agencies and academic groups.  

Our COVID-19 Serology Laboratory also worked with the U.S. Food and Drug Administration and the Centers for Disease Control and Prevention to develop performance evaluation panels and to evaluate commercial serology assays submitted to Food and Drug Administration for independent validation. 

We supported establishment of the NCI Serological Sciences Network and oversee the SeroNet Coordinating Center, which provides program logistic support.

The HPV Serology Laboratory also leads an HPV Serology Standardization initiative in collaboration with the NCI and the Bill and Melinda Gates Foundation.